These dual-targeting probes can bind simultaneously or separately to different target structures on tumor cells, such as FAPI-RGD that binds both FAP and integrin αvβ3, prostate cancer dual-target probes for prostate-specific membrane antigen (PSMA) and GPPR, and FAPI-LM3 targeting both SSTR2 and FAP. This evidence concerns the gene FOLH1 and prostate carcinoma.